Shots:

• Transgene to receive $10M upfront & $3M preclinical milestones- providing its oncolytic virus expertise with Vaccinia Virus (TK-- RR-) double-deleted backbone and will take care of in-vitro pre-clinical development
• AZ has an option to select 5 oncolytic immunotherapies based on Invir.IO and will be responsible for its in-vivo pre and clinical development with the commercialization of candidates. If AZ exercises its option- Transgene will receive option exercise payment- development & commercial milestones and royalties on sales of each candidate
• Transgene’s Invir.IO utilizes viral vector technology to design therapies for multifunctional oncolytic viruses. Transgene has various pre and clinical -stage vaccines including TG4010- TG4001 & TG1050- TG6002 for NSCLC- HPV+ head and neck cancers & hepatitis B and solid tumors respectively

Ref: BusinessWire | Image: AstraZeneca